---
title: "B. Riley Securities maintains Buy rating on OptimizeRx, $11 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300460367.md"
description: "B. Riley Securities maintains a Buy rating on OptimizeRx with an $11 price target, implying 40.8% upside from the September 28 close of $7.81. The firm cites strong margin expansion, with EBITDA margins rising from 13% to 24% year-over-year, and potential upside recovery if a lapsed major customer relationship improves."
datetime: "2026-09-29T15:45:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300460367.md)
  - [en](https://longbridge.com/en/news/300460367.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300460367.md)
generator: "portal-rs"
---

# B. Riley Securities maintains Buy rating on OptimizeRx, $11 price target

B. Riley Securities maintained their Buy rating on OptimizeRx's stock with a price target of $11.00.

The price target implies an upside of 40.8% from the Sep 28 close of $7.81.

**Key takeaways from the analyst note**

**Strong Margin Expansion**: OptimizeRx has demonstrated significant improvements in its margin structure, with EBITDA margins expanding from approximately 13% to 24% year-over-year. This margin resilience, even amid revenue challenges, indicates effective cost management and a shift towards higher-margin solutions, making the stock an attractive buy.

**Potential for Upside Recovery**: The company has refrained from including any contributions from a lapsed major customer in its forecasts, presenting a clear path for upside potential. Should this customer relationship show signs of recovery, it would represent a substantial positive revision to revenue estimates, further justifying the Buy rating.

Explore more price target data and ratings for OptimizeRx on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [OPRX.US](https://longbridge.com/en/quote/OPRX.US.md)

## Related News & Research

- [OptimizeRx expands Natural Language Audience Builder to add DTC targeting workflow](https://longbridge.com/en/news/298915456.md)
- [OptimizeRx integrates with Trade Desk OpenPath to offer authenticated EHR ad inventory](https://longbridge.com/en/news/299763946.md)
- [Google Stock Gets $420 Price Target from BNP Paribas – Here's Why](https://longbridge.com/en/news/300731266.md)
- [Why Nvidia Stock Is Rising Today and Why Morgan Stanley Reinstates NVDA as a "Top Pick"](https://longbridge.com/en/news/300784037.md)
- [RKLB Stock: Citi Calls It a "Core Holding for Space Bulls," Assigns Buy Rating](https://longbridge.com/en/news/300693659.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**